Navigation Links
Tumor target suggests personalized treatment for melanoma
Date:6/15/2010

Identification of a key player in a signaling pathway involved in the development of melanoma the deadliest form of skin cancer may offer hope for new targeted melanoma therapies.

Ann Richmond, Ph.D., and colleagues at Vanderbilt-Ingram Cancer Center report that a signaling molecule, known as IKKβ, is essential for melanoma tumor development in a mouse model of the disease. The results, published June 7 in the Journal of Clinical Investigation, also point to ways of targeting therapies that inhibit IKKβ toward the patients most likely to benefit from them based on their genetic profile.

Melanoma is the deadliest form of skin cancer and incredibly difficult to treat successfully once the tumor has spread beyond the skin.

Prior studies have shown that the NF-κB signaling pathway centered on the protein NF-κB, which regulates gene expression is abnormally activated in tumor cells; the pathway is turned "on" constantly, even at times it should be turned "off." This activation often results from abnormal activation of another enzyme in the pathway, IKKβ.

Just how NF-κB contributes to tumor progression has been unclear. And with drugs that inhibit this pathway entering clinical trials, a clearer picture of its function in tumor progression is needed.

To better understand the role of this pathway in particular, of IKKβ's role Richmond's lab developed a mouse model that mimics the genetic alterations involved in melanoma development in humans.

Jinming Yang, Ph.D., a staff scientist in Richmond's lab, led the effort to generate these mice, which lack the tumor suppressor INK4a/ARF (commonly lost in melanomas) and have the Ras/Raf pathway activated (which is activated in about 70 percent of melanoma lesions).

The researchers then added the ability to "turn off" IKKβ only in melanocytes, the pigment-producing skin cells in which melanomas initiate, simply by treating the mice with an antibiotic.

Mice with normal IKKβ activity developed "loads and loads of melanoma tumors all over their bodieson the tail, the ear, and anywhere melanocytes are," said Richmond, an Ingram Professor of Cancer Biology at Vanderbilt University Medical Center and a senior career research scientist with the Department of Veterans Affairs.

But mice in which IKKβ was "turned off" developed no melanoma tumors.

They also found that treating mice with normal IKKβ activity with small molecule inhibitors of the enzyme could inhibit the growth of melanoma lesions.

"This shows for the first time that you have to have IKKβ for Ras-induced melanoma, suggesting that there's a way to specifically target melanoma lesions," she said.

However, the experiments identified an important caveat: blocking IKKβ only seemed to protect against melanoma formation when another tumor suppressor, p53, is expressed.

Since mutations that disrupt p53 are sometimes found in melanomas, this suggests that therapies targeting IKKβ or the NF-κB pathway in general would need to be limited to tumors with normal p53.

Richmond cautions, "With NF-κB inhibitors entering clinical trials at this time, it is imperative that these data be taken into consideration for patient selection or evaluation of response in these trials."

Richmond is collaborating with Vanderbilt-Ingram Cancer Center investigators Mark Kelley, M.D., and Jeffrey Sosman, M.D., to identify, in human tumor samples, which tumors would respond to targeted inhibitors of the Ras/Raf and NF-κB pathways.

Such information could aid in diagnosis and "be used to deliver personalized medicine" to melanoma patients in the future, she said.

"We're passionate about (IKKβ inhibitors) possibly going forward, maybe not as a single agent, but in combination (treatments). As we are able to better predict which patients will respond to which drugs, there's real hope there."


'/>"/>

Contact: Dagny Stuart
dagny.stuart@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Taking aim at metastatic lung tumors
2. Solid tumor modeling focus of workshops
3. Drug that restricts blood supply to prostate tumors delays disease progression
4. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
5. FDA approves first human neural stem cell clinical trial to treat brain tumors
6. HPV-positive tumor status indicates better survival in patients with oropharyngeal cancer
7. Detecting tumors faster
8. Drug that helps metastatic colon cancer of no benefit in less advanced tumors
9. Bone drug suppresses wandering tumor cells in breast cancer patients
10. Study: Prostate cancer patients weight linked to tumor size
11. Size of Prostate Tumor Linked to Patients Weight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of ... conviction that the full potential of specialty and orphan brands can only be achieved ... , “The Unifying Effect is at the heart of a true partnership between ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The Hong ... the first 3D printing facility among higher education institutions in Hong Kong to support ... in terms of the range and quantity of facilities in Hong Kong. , ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the medical ... the highly regarded and well renowned Asian distributor, Discovery Sleep. The ... Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence with a dedicated, ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... Providing ... not understand the estate planning process, or where to even begin. “Now more than ... if you are to properly protect yourself and your family,” said attorney Lisa Edgar ...
(Date:4/21/2017)... ... 21, 2017 , ... Each year, everyone is urged to give back to ... and look forward to a better future. However, supporting the environment should be an ... quality can be two to five times more polluted than outdoor air, reports the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
Breaking Medicine Technology: